GoodRx (GDRX) Expected to Release Quarterly Earnings on Wednesday

GoodRx (NASDAQ:GDRX) is anticipated to issue its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect GoodRx to post earnings of $0.08 per share and revenue of $193.2310 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.07 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.07. The business had revenue of $194.01 million during the quarter, compared to analyst estimates of $185.40 million. GoodRx had a net margin of 2.61% and a return on equity of 7.90%. The company’s revenue was down 4.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.09 earnings per share. On average, analysts expect GoodRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

GoodRx Price Performance

Shares of GDRX stock opened at $3.07 on Monday. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of 51.18, a PEG ratio of 1.42 and a beta of 1.60. GoodRx has a one year low of $1.77 and a one year high of $5.81. The company’s fifty day moving average price is $2.89 and its 200-day moving average price is $2.52. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.47 and a quick ratio of 1.47.

Hedge Funds Weigh In On GoodRx

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in GoodRx by 7.3% in the 3rd quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company’s stock valued at $38,947,000 after acquiring an additional 624,182 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of GoodRx by 4.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company’s stock valued at $24,001,000 after purchasing an additional 184,734 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of GoodRx by 6.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,650,452 shares of the company’s stock valued at $7,183,000 after purchasing an additional 152,934 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of GoodRx by 188.0% in the fourth quarter. AQR Capital Management LLC now owns 1,158,546 shares of the company’s stock worth $3,140,000 after purchasing an additional 756,209 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of GoodRx by 22.1% in the fourth quarter. Geode Capital Management LLC now owns 1,135,563 shares of the company’s stock worth $3,078,000 after buying an additional 205,628 shares in the last quarter. Institutional investors own 63.77% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GDRX. Citigroup reiterated a “buy” rating on shares of GoodRx in a research note on Thursday, July 23rd. The Goldman Sachs Group restated a “neutral” rating and issued a $3.50 price objective on shares of GoodRx in a research report on Friday, May 8th. TD Cowen upped their price objective on GoodRx from $3.00 to $4.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Finally, Weiss Ratings cut GoodRx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, July 23rd. Five analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, GoodRx has an average rating of “Hold” and an average price target of $3.81.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.